At Urology of Virginia, research studies form a vital component of our mission. These studies, referred to as clinical trials, are designed by physicians and researchers to investigate new medical therapies. Well-designed clinical trials offer the newest, most promising drugs and treatments for urological conditions to our community.
Our staff’s experienced investigators and certified clinical research coordinators closely monitor participating patients during the course of a study period. All clinical trials are conducted according to the principles of Good Clinical Practice (GCPs) as mandated by the FDA.
For questions and information about our clinical trials, please contact us at research@urologyofva.net
There is a new research study in Virginia Beach for men living with BPH (enlarged prostate).
No cost to participate. Learn more. 757-452-3464.
- Participants have access to advanced medications or devices before they become available to the public.
- Clinical study procedures may be provided to you at no cost.
- Participants often express enthusiasm for contributing to medical science.
- Today’s clinical research can positively impact future generations.
Enrolling Clinical Studies at Urology of Virginia
Janssen SunRISe-2: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.
Get detailed information about this clinical trial»
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B).
Get detailed information about this clinical trial»
Study of PF-06801591 in Combination with BCG in Participants with Non-muscle Invasive Bladder Cancer (NMIBC)
The study is designed to demonstrate that PF-06801591 plus Bacillus Calmette Guerin (BCG) (induction and maintenance periods) is superior to BCG alone (induction and maintenance periods) in prolonging event free survival (EFS) in participants with high-risk naïve non-muscle invasive bladder cancer (NMIBC) and to demonstrate that PF-06801591 plus BCG (induction period only) is superior to BCG alone (induction and maintenance periods) in prolonging EFS in participants with high-risk NMIBC.
Get detailed information about this clinical trial»
Convergent Genomics INSITE: Specimen Collection for Validation of UriSeq
Collection of urine and tumor specimens to validate a urine sequencing diagnostic for detection and surveillance of carcinoma of the urinary tract.
Expected Management
Canary PASS:
A multicenter, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate cancer at diagnosis. The objective is to discover and confirm biomarkers that predict aggressive disease.
Hormone Therapy (ADT)
Veru, Inc.: Open label, Proof of concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men with Advanced Prostate Cancer
This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain and maintain serum total testosterone levels within castrate range (<50ng/dL) in men with advanced prostate cancer. Stage 1 of the study will assess the effect of VERU-100 at various doses. Stage 2 will further assess the efficacy of the effective doses of VERU-100 in an expanded patient population.
Get detailed information about this clinical trial»
PROTEUS: A Study of Apalutamide in Participants With High Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
The purpose of this study is to determine if treatment with androgen deprivation therapy (ADT) plus apalutamide (with or without abiraterone acetate with prednisone [AAP]) before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to ADT plus placebo.
Get detailed information about this clinical trial»
Janssen APA RP: Study of Apalutamide (Adjuvant Treatment) and ADT in Participants Who Have Undergone Radical Prostatectomy for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
The purpose of this study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence free rate.
Get detailed information about this clinical trial»
Metastatic disease: Cancer that has spread to other areas
Tavanta TAVT-45 (Abiraterone Acetate) Granules in Patients with Prostate Cancer
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
Get detailed information about this clinical trial»
Veru, Inc. VERACITY: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Purpose of study is to demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.
Get detailed information about this clinical trial»
Clovis TRITON3: “A Study of Rucaparib Versus Physician’s Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency”
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician’s choice of abiraterone acetate, enzalutamide, or docetaxel. Patients will be screened for the deleterious mutation in a BRCA1/2 or ATM gene to qualify.
Get detailed information about this clinical trial»
MAGNITUDE: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo.
Interstitial Cystitis
EpicGenetics FM/a Test: A Determination of the Incidence of Fibromylagia in Individuals with Interstitial Cystitis
The purpose of the study is to determine if patients with interstitial cystic have evidence of fibromyalgia.
Stone Disease
Allena ALLN-177-302: Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2)
The purpose of this study is to determine the efficacy, durability and long term safety of reloxaliase in patients with enteric hyperoxaluria.
Get detailed information about this clinical trial»
Calyxo ASPIRE:Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)
The purpose of the study is to compare the effectsof a treatment for removing kidney stones called the SURE procedure for stone evacuation to the standard treatment using a basket for stone removal.The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a laser ureteroscopy surgery.
Get detailed information about this clinical trial»
Incontinence
CELLEBRATE: Adaptive Design Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) compared to a placebo in the treatment of stress urinary incontinence (SUI) in adult female patients. Half of the participants will receive AMDC-USR (injections with cells) and the other half will receive a placebo. Participants who are randomly chosen to receive an injection with placebo will have the option to receive an injection with their cells after completion of the blinded portion of their study participation (12 months).
Get detailed information about this clinical trial»
Spinal Singularity FREEDOM: Connected Catheter-Safety and Effectiveness Study
The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a sterile, extended-use device that resides fully internally to the male lower urinary tract for an intended use life of up to 7 days per catheter.
Get detailed information about this clinical trial»
Urethral Stricture
No Enrolling Studies at This Time
Pelvic Organ Prolapse
No Enrolling Studies at This Time
Hypogonadism
No Enrolling Studies at This Time
Nocturia
No Enrolling Studies at This Time
BPH (Enlarged Prostate)
Zenflow BREEZE: Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
Get detailed information about this clinical trial»
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
